Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies

British Journal of Haematology

Volumn 100, Issue 4, 1998, Pages 784-792

  Buggins, A G S ^a   Hirst, W J R ^a   Pagliuca, A ^a   Mufti, G J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CD3 zeta; Myeloid malignancies; NK cells; Protein tyrosine kinases; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; PROTEIN TYROSINE KINASE; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER GRADING; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 0031906610     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00654.x     Document Type: Article

References (45)

1. Anderson, P., Blue, M., O'Brian, C. & Schlossman, S. (1989) Monoclonal antibodies reactive with the T-cell receptor ζ chain: production and characterization using a new method. Journal of Immunology, 143, 1899-1904.
2. Aoe, T., Okamoto, Y. & Saito, T. (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. Journal of Experimental Medicine, 181, 1881-1886.
3. Appleby, M.W., Gross, J.A., Cooke, M.P., Levin, S.D., Qian, X. & Perlmutter, R.M. (1992) Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell, 70, 751-763.
4. Ariad, S., Dajee, D., Willem, P. & Bezwoda, W.R. (1993) Lack of involvement of T-lymphocytes in the leukemic population during prolonged chronic phase of Philadelphia chromosome positive chronic myeloid leukemia. Leukemia and Lymphoma, 10, 217-221.
5. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
6. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620-624.
7. Chang, W.C., Fujimiya, Y., Casteel, N. & Pattengale, P. (1989) Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells. International Journal of Cancer, 43, 591-597.
8. Colombat, P.H., Renoux, M., Lamagnere, J.P. & Renoux, G. (1988) Immunologic indices in myelodysplastic syndromes. Cancer, 61, 1075-1081.
9. + T cells due to ZAP-70 deficiency. Cell Immunology, 165, 110-117.
10. Elder, M.E., Lin, D., Clever, J., Chan, A.C., Hope, T.J., Weiss, A. & Parslow, T.C. (1994) Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science, 264, 1596-1599.
11. Farace, F., Angevin, E., Vanderplancke, J., Escudier, B. & Triebel, F. (1994) The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. International Journal of Cancer, 59, 752-755.
12. Finke, J.H., Zea, A.H., Stanley, J., Longo, D.L., Mizoguchi, H., Tubbs. R.R., Wiltrout, R.H., O'Shea, J.J., Kudoh, S., Klein, E., Bukowski, R.M. & Ochoa, A.C. (1995) Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Research, 53, 5613-5616.
13. Fontana, L., De Sanctis, G., De Rossi, G., Bottari, V., Petti, M.C., Ensoli, F., Pasqualetti, D. & Mandelli, F. (1989) Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes. Acta Haematologica, 82, 1-6.
14. Franco, J.L., Ghosh, P., Wiltrout, R.H., Carter, C.R., Zea, A.H., Momozaki, N., Ochoa, A.C., Longo, D.L., Sayers, T.J. & Komschlies, K.L. (1995) Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Research, 55, 3840-3846.
15. Garicochea, B., Chase, A., Lazaridou, A. & Goldman, J.M. (1994) T lymphocytes in chronic myelogenous leukemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridisation in 14 patients. Leukemia, 8, 1197-1201.
16. Guarini, A., Riera, L., Cignetti, A., Montacchini, L., Massaia, M. & Foa, R. (1997) Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood, 89, 212-218.
17. Hamblin, T.J. (1992) Immunological abnormalities in myelodysplastic syndromes. The Myelodysplastic Syndromes (ed. by G. J. Mufti and D. A. G. Galton). p. 97. Churchill Livingstone, Edinburgh.
18. Isakov, N., Wange, R.L. & Samelson, L.E. (1994) The role of tyrosine kinases and phosphotyrosine-containing recognition motifs in regulation of the T cell-antigen receptor-mediated signal transduction pathway. Journal of Leukocyte Biology, 55, 265-271.
19. Kibbelaar, R.E., van Kamp, H., Dreef, E.J., de Groot Swings, G., Kluin Nelemans, J.C., Beverstock, G.C., Fibbe, W.E. & Kluin, P.M. (1992) Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood, 79, 1823-1828.
20. Kolenko, V., Wang, Q., Riedy, M.C., O'Shea, J., Ritz, J., Cathcart, M.K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., Bukowski, R. & Finke, J. (1997) Tumor induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. Journal of Immunology, 159, 3057-3067.
21. Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P. & Kiessling, R. (1996) Hydrogen peroxide secreted by tumour-derived macrophages down modulates signal-transduction zeta molecules and inhibits tumour-specific T cell and natural killer cell-mediated cytotoxicity. European Journal of Immunology, 26, 1308-1313.
22. Levey, D.L., & Srivastava, P.K. (1995) T cells from late tumor-bearing mice express normal levels of p56lck. p59fyn. ZAP-70, and CD3 zeta despite suppressed cytolytic activity. Journal of Experimental Medicine, 182, 1029-1036.
23. Levey, D.L., & Srivastava, P.K. (1996) Alterations in T-cells of cancer-bearers: whence specificity? Immunology Today, 17, 365-368.
24. Love, P.E., Shores, E.W, Lee, E.J., Grinberg, A., Munitz, T.I., Westphal, H. & Singer, A. (1994) Differential effects of zeta and eta transgenes on early alpha/beta T cell development, Journal of Experimental Medicine, 179, 1485-1494.
25. Maccubbin, D.L., Mace, K.F., Ehrke, M.J. & Mihich, E. (1989) Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Research, 49, 4216-4224.
26. MacKinney, A.A., Jr, Clark, S.S., Borcherding, W., Fizzotti, M. & Hong, R. (1993) Simultaneous demonstration of the Philadelphia chromosome in T, B, and myeloid cells. American Journal of Hematology, 44, 48-52.
27. Matsuda, M., Petersson, M., Lenkei, R., Taupin, J.L., Magnusson, I., Mellstedt, H., Anderson, P. & Kiessling, R. (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. International Journal of Cancer, 61, 765-772.
28. Miescher, S., Whiteside, T.L., Carrel, S. & von Fliedner, V. (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. Journal of Immunology, 136, 1899-1907.
29. Mizoguchi, H., O'Shea, J.J., Longo, D.L., Loeffler, C.M., McVicar, D.W. & Ochoa, A.C. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-hearing mice. Science, 258, 1795-1798.
30. Molina, T.J., Kishihara, K., Siderovski, D.P., van Ewijk, W., Narendran, A., Timms, E., Wakeham, A., Paige, C.J., Hartmann, K.U., Veillette, A., Davidson, D. & Mak, T.W. (1992) Profound block in thymocyte development in mice lacking p56lck. Nature, 357, 161-164.
31. Nakagomi, H., Petersson, M., Magnusson, I., Jublin, C., Matsuda, M., Mellstedt, H., Taupin, J.L. Vivier, E., Anderson, P. & Kiessling, R. (1995) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Research, 53, 5610-5612.
32. Ogata, K., Tamura, H., Yokose, N., An, E., Dan, K., Hamaguchi, H., Sakamaki, H., Onozawa, Y., Clark, S.C. & Nomura, T. (1995) Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes. British Journal of Heamatology, 90, 15-21.
33. Rajaram, N., Tatake, R.J., Advani, S.H., Naik, S.L. & Gangal, S.G. (1990) Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunology and Immunotherapy, 31, 44-48.
34. Rambotti, P., Liberati, A.M., Velardi, A., Ballatori, E., Martelli, M.F., Grignani, F. & Davis, S. (1982) Cell membrane markers and phytohemagglutinin reactivity of circulating lymphocytes from chronic myelocytic leukemia patients. Cancer, 49, 708-713.
35. Renner, C., Ohnesorge, S., Held, G., Bauer, S., Jung, W., Pfitzenmeier, J.P. & Pfreundschuh, M. (1996) T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD 3 and CD 28. Blood, 88, 236-241.
36. Salvadori, S., Gansbacher, B., Pizzimenti, A.M. & Zier, K.S. (1944) Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. Journal of Immunology, 153, 5176-5182.
37. Sorskaar, D., Forre, O., Albrechtsen, D. & Stavem, P. (1986) Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia. Scandinavian Journal of Haematology, 37, 154-161.
38. Stupp, Y., Rosenkovitch, E. & Izak, G. (1978) Natural killer activity in patients with acute myelocytic leukaemia. Israel Journal of Medical Science, 14, 1212-1215.
39. Takasugi, M., Ramseyer, A. & Takasugi, J. (1977) Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Research, 57, 413-418.
40. Tartour, E., Latour, S., Mathiot, C., Thiounn, N., Mosseri, V., Joyeux, I., D'Enghien, C.D., Lee, R., Debre, B. & Fridman, W.H. (1995) Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. International Journal of Cancer, 63, 205-212.
41. Verfaillie, C., Kay, N., Miller, W. & McGlave, P. (1990) Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood, 76, 401-408.
42. Wang, Q., Stanley, J., Kudoh, S., Myles, J., Kolenko, V., Yi, T., Tubbs, K., Bukowski, R. & Finke. J. (1995) T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. Journal of Immunology, 155, 1382-1392.
43. Weiss, A. & Littman, D.R. (1994) Signal transduction by lymphocyte antigen receptors. Cell, 76, 263-274.
44. Whitcomb, M.E. & Parker, R.L. (1977) Abnormal lymphocyte protein synthesis in bronchogenic carcinoma. Cancer, 40, 3014-3018.
45. Zier, K., Gansbacher, B. & Salvadori, S. (1996) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunology Today, 17, 39-45.